Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2903931rdf:typepubmed:Citationlld:pubmed
pubmed-article:2903931lifeskim:mentionsumls-concept:C0013227lld:lifeskim
pubmed-article:2903931lifeskim:mentionsumls-concept:C0439849lld:lifeskim
pubmed-article:2903931lifeskim:mentionsumls-concept:C0031013lld:lifeskim
pubmed-article:2903931lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:2903931lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:2903931lifeskim:mentionsumls-concept:C0205464lld:lifeskim
pubmed-article:2903931lifeskim:mentionsumls-concept:C0445223lld:lifeskim
pubmed-article:2903931lifeskim:mentionsumls-concept:C1552599lld:lifeskim
pubmed-article:2903931lifeskim:mentionsumls-concept:C1704787lld:lifeskim
pubmed-article:2903931lifeskim:mentionsumls-concept:C0205358lld:lifeskim
pubmed-article:2903931lifeskim:mentionsumls-concept:C0871161lld:lifeskim
pubmed-article:2903931lifeskim:mentionsumls-concept:C0243072lld:lifeskim
pubmed-article:2903931pubmed:issue12lld:pubmed
pubmed-article:2903931pubmed:dateCreated1989-1-12lld:pubmed
pubmed-article:2903931pubmed:abstractTextIn the hope of reducing the toxicity of perhexiline, a series of 27 cyclohexylaralkylamines II based on the "soft drug" concept and incorporating an amide function were synthesized. In a preliminary screening, compounds were evaluated for their alpha-adrenolytic activities. Several derivatives, especially N-(cyclohexylphenylmethyl)-2-(cyclohexyl-methylamino)acetamide (3), N-(cyclohexylphenylmethyl)-2-(homoveratrylmethylamino)acetam ide (7), and N-[2-(cyclohexylamino)ethyl]-alpha-cyclohexylbenzeneacetamide (23) had the same activity range as perhexiline in vitro in rat aorta strips. The in vitro metabolism of these three molecules was then investigated and compared to that of perhexiline. The effect upon the alpha-adrenolytic activity of introducing various N-aralkylamine groups on II was examined. Structure/activity relationships are discussed.lld:pubmed
pubmed-article:2903931pubmed:languageenglld:pubmed
pubmed-article:2903931pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2903931pubmed:citationSubsetIMlld:pubmed
pubmed-article:2903931pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2903931pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2903931pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2903931pubmed:statusMEDLINElld:pubmed
pubmed-article:2903931pubmed:monthDeclld:pubmed
pubmed-article:2903931pubmed:issn0022-2623lld:pubmed
pubmed-article:2903931pubmed:authorpubmed-author:SchwartzJJlld:pubmed
pubmed-article:2903931pubmed:authorpubmed-author:LeclercGGlld:pubmed
pubmed-article:2903931pubmed:authorpubmed-author:DeckerNNlld:pubmed
pubmed-article:2903931pubmed:authorpubmed-author:MarciniakGGlld:pubmed
pubmed-article:2903931pubmed:authorpubmed-author:DecolinDDlld:pubmed
pubmed-article:2903931pubmed:issnTypePrintlld:pubmed
pubmed-article:2903931pubmed:volume31lld:pubmed
pubmed-article:2903931pubmed:ownerNLMlld:pubmed
pubmed-article:2903931pubmed:authorsCompleteYlld:pubmed
pubmed-article:2903931pubmed:pagination2289-96lld:pubmed
pubmed-article:2903931pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:2903931pubmed:meshHeadingpubmed-meshheading:2903931-...lld:pubmed
pubmed-article:2903931pubmed:meshHeadingpubmed-meshheading:2903931-...lld:pubmed
pubmed-article:2903931pubmed:meshHeadingpubmed-meshheading:2903931-...lld:pubmed
pubmed-article:2903931pubmed:meshHeadingpubmed-meshheading:2903931-...lld:pubmed
pubmed-article:2903931pubmed:meshHeadingpubmed-meshheading:2903931-...lld:pubmed
pubmed-article:2903931pubmed:meshHeadingpubmed-meshheading:2903931-...lld:pubmed
pubmed-article:2903931pubmed:meshHeadingpubmed-meshheading:2903931-...lld:pubmed
pubmed-article:2903931pubmed:meshHeadingpubmed-meshheading:2903931-...lld:pubmed
pubmed-article:2903931pubmed:meshHeadingpubmed-meshheading:2903931-...lld:pubmed
pubmed-article:2903931pubmed:meshHeadingpubmed-meshheading:2903931-...lld:pubmed
pubmed-article:2903931pubmed:meshHeadingpubmed-meshheading:2903931-...lld:pubmed
pubmed-article:2903931pubmed:meshHeadingpubmed-meshheading:2903931-...lld:pubmed
pubmed-article:2903931pubmed:meshHeadingpubmed-meshheading:2903931-...lld:pubmed
pubmed-article:2903931pubmed:year1988lld:pubmed
pubmed-article:2903931pubmed:articleTitleSynthesis and pharmacological properties of "soft drug" derivatives related to perhexiline.lld:pubmed
pubmed-article:2903931pubmed:affiliationInstitut de Pharmacologie (UA 589 CNRS), Départment de Pharmacochimie, Faculté de Médecine, Strasbourg, France.lld:pubmed
pubmed-article:2903931pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2903931pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:2903931pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:2903931pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:2903931lld:chembl